tesamorelin vs cjc 1295 and ipamorelin CJC-1295: Research Compared Tesamorelin vs Sermorelin vs CJC-1295

It is not the subject of a USP or NF monograph, is not a component of any FDA-approved drug product, and does not appear on the 503A bulk drug substance list for compounding pharmacies

Journal of Orthopaedic Research

long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts

HSP18.5 and the transcripts encoding two large HSPs (HSP90C and mtHSC70-1) were used as negative controls